Aligos Therapeutics ALGS 深 沪
已收盘 11-13 16:00:00 美东时间
2.10
+0.120
+6.06%
华盛通- 最 高2.245
- 今 开2.09
- 成交量 5.75万股
- 最 低 1.98
- 昨 收 1.98
- 总市值 1312.18万
- 52周最高 13.6892
- 市盈率 静 --
- 换手率 0.92%
- 52周最低 1.92
- 委 比 -66.67%
- 总股本 624.85万
- 历史最高 937.75
- 量 比 0.34
- 振 幅 13.38%
- 历史最低 1.92
- 每 手 1
- 风险率 1.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aligos Therapeutics 2026财年第3季度营收286.9万美元，同比增长287.18%
最新财报显示，Aligos Therapeutics 2026财年第3季度实现： 营业收入：286.9万美元 同比：增长287.18% 净利润：-2186万美元...
今天 02:00
Aligos Therapeutics收跌2.95%，成交额60.75万美元
11月10日，Aligos Therapeutics（ALGS）收跌2.95%，报3.95美元，成交额60.75万美元，市值2466.62万美元。 行情数据 ...
11-10 08:50
Aligos Therapeutics Q3 EPS $(2.09) Beats $(2.28) Estimate, Sales $2.830M Miss $5.543M Estimate
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(2.09) per share which beat the analyst consensus estimate of $(2.28) by 8.33 percent. This is a 31.25 percent increase over losses of $(3.04) per share from the same period last year. The company reported quarterly sales of $2.830 mill...
11-06 21:36
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026
Aligos Therapeutics announced positive data from five presentations at the AASLD Liver Meeting 2026, highlighting advancements in chronic HBV treatment. Pevifoscorvir sodium showed potential in reducing pro-inflammatory cytokines and inhibiting viral DNA forms linked to disease progression. ALG-170675, a next-generation antisense oligonucleotide, demonstrated superior HBsAg knockdown in preclinical studies. Additional research showcased innovativ...
11-05 21:05
Aligos Therapeutics收跌4.17%，成交额11.02万美元
11月3日，Aligos Therapeutics（ALGS）收跌4.17%，报4.6美元，成交额11.02万美元，市值2872.52万美元。 行情数据 • 开...
11-03 08:37
Aligos Therapeutics收跌2.72%，成交额15.41万美元
10月27日，Aligos Therapeutics（ALGS）收跌2.72%，报4.65美元，成交额15.41万美元，市值2903.74万美元。 行情数据 ...
10-27 07:40
Aligos Therapeutics收跌9.83%，成交额34.66万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:43
Aligos Therapeutics Announces Acceptance Of Five Abstracts At American Association For Study Of Liver Disease's The Liver Meeting
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced five abstracts have been accepted for presentation at the American Association for the Study of Liv...
10-06 04:08
Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026
Aligos Therapeutics announced that five abstracts on its therapies for chronic hepatitis B and delta virus infections have been accepted for presentation at AASLD’s The Liver Meeting 2026. The abstracts highlight pevifoscorvir sodium’s potential as a first-in-class small molecule CAM-E and ALG-170675 as a best-in-class antisense oligonucleotide, showcasing their efficacy in reducing viral markers and suppressing HBV DNA. Preclinical data on ALG-2...
10-05 20:05
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Shares of Lobo Technologies Ltd (NASDAQ:LOBO) rose sharply in pre-market trading after the company reported a year-over-year increase in H1 financial results. Lobo EV Technologies posted a H1 loss of 7 cents per share, versus a year-ago loss of 28 cents per share. The company’s sales rose to $14.587...
09-21 17:01
